These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32690107)

  • 21. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop.
    Mikami K; Sturdy S
    Res Involv Engagem; 2017; 3():14. PubMed ID: 29062539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
    Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
    Front Public Health; 2020; 8():162. PubMed ID: 32457865
    [No Abstract]   [Full Text] [Related]  

  • 25. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
    Adkins EM; Nicholson L; Floyd D; Ratcliffe M; Chevrou-Severac H
    Clinicoecon Outcomes Res; 2017; 9():327-342. PubMed ID: 28652787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
    Wonder M; Chin G
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
    Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
    Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health Technology Assessment and Appraisal of Therapies for Rare Diseases.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Adv Exp Med Biol; 2017; 1031():221-231. PubMed ID: 29214575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
    Morrell L; Wordsworth S; Fu H; Rees S; Barker R
    BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB).
    Xie F; Zoratti M; Chan K; Husereau D; Krahn M; Levine O; Clifford T; Schunemann H; Guyatt G
    Med Decis Making; 2019 May; 39(4):370-378. PubMed ID: 30902030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.
    Kogushi K; Ogawa T; Ikeda S
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):455-471. PubMed ID: 31496361
    [No Abstract]   [Full Text] [Related]  

  • 38. European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
    Cleemput I; Franken M; Koopmanschap M; le Polain M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):358-66. PubMed ID: 22980497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
    Gammie T; Lu CY; Babar ZU
    PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.